Published in J Clin Invest on March 01, 1995
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest (1996) 2.63
Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest (1996) 2.09
Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest (1998) 1.94
Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res (2012) 1.69
Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest (1997) 1.66
Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest (1996) 1.57
Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest (1998) 1.47
Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. J Biol Chem (2008) 1.31
Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A (1998) 1.29
Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. J Clin Invest (1999) 1.28
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol (2008) 1.14
A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart (1999) 1.14
Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. J Clin Invest (1997) 1.12
Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. J Cell Biol (2002) 1.09
Suppression of muscle hypercontraction by mutations in the myosin heavy chain gene of Drosophila melanogaster. Genetics (2003) 1.05
Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J (1998) 1.04
Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med (2001) 1.00
Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution. Nature (2016) 0.98
Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. J Cell Biol (2012) 0.94
Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart (1998) 0.85
Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. Sci Adv (2015) 0.85
Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation. J Physiol (2014) 0.85
Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation? J Muscle Res Cell Motil (2014) 0.82
Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes. J Physiol (2003) 0.82
Titin mutations: the fall of Goliath. Heart Fail Rev (2015) 0.81
Regional left ventricular contractile dynamics in hypertrophic cardiomyopathy evaluated by magnetic resonance imaging. Heart Vessels (1996) 0.81
Cell-intrinsic functional effects of the α-cardiac myosin Arg-403-Gln mutation in familial hypertrophic cardiomyopathy. Biophys J (2012) 0.80
Structural basis for myopathic defects engendered by alterations in the myosin rod. J Mol Biol (2011) 0.79
Hypertrophic cardiomyopathy: how do mutations lead to disease? Arq Bras Cardiol (2014) 0.78
Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy. Heart (1997) 0.77
Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development. Front Physiol (2014) 0.76
HEART DISEASE. Throttling back the heart's molecular motor. Science (2016) 0.75
Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy. Sci Adv (2017) 0.75
Transcriptome analysis reveals potential mechanisms underlying differential heart development in fast- and slow-growing broilers under heat stress. BMC Genomics (2017) 0.75
A Combined Linkage and Exome Sequencing Analysis for Electrocardiogram Parameters in the Erasmus Rucphen Family Study. Front Genet (2016) 0.75
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Structure of the actin-myosin complex and its implications for muscle contraction. Science (1993) 11.30
The velocity of unloaded shortening and its relation to sarcomere length and isometric force in vertebrate muscle fibres. J Physiol (1979) 6.89
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77
The relation between stiffness and filament overlap in stimulated frog muscle fibres. J Physiol (1981) 5.48
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med (1992) 4.20
Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers. Biophys J (1983) 3.33
Chemically skinned mammalian skeletal muscle. I. The structure of skinned rabbit psoas. Tissue Cell (1979) 2.95
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67
Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature (1993) 2.29
Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation (1994) 2.21
Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest (1993) 2.04
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A (1993) 1.62
Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet (1993) 1.58
Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol (1979) 1.55
A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A (1993) 1.47
Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation (1992) 1.29
Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation (1994) 1.26
Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Circ Res (1992) 1.16
Novel missense mutation in cardiac beta myosin heavy chain gene found in a Japanese patient with hypertrophic cardiomyopathy. Biochem Biophys Res Commun (1992) 1.12
Myosin phosphorylation in permeabilized rabbit psoas fibers. Am J Physiol (1985) 1.05
Electrophoretic separation and immunological identification of type 2X myosin heavy chain in rat skeletal muscle. Biochim Biophys Acta (1990) 1.03
Hypertrophic cardiomyopathy mutation is expressed in messenger RNA of skeletal as well as cardiac muscle. Circulation (1993) 0.92
Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A (1993) 7.18
Myosin VI is an actin-based motor that moves backwards. Nature (1999) 5.69
The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature (1991) 5.40
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet (2001) 5.18
The kinetic mechanism of myosin V. Proc Natl Acad Sci U S A (1999) 4.56
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
A 35-A movement of smooth muscle myosin on ADP release. Nature (1995) 4.28
Myosin VI is a processive motor with a large step size. Proc Natl Acad Sci U S A (2001) 3.95
Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A (1998) 3.74
Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation (1994) 3.41
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest (1999) 3.06
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02
Kinetic mechanism and regulation of myosin VI. J Biol Chem (2001) 2.93
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67
The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell (2001) 2.56
Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol (1997) 2.32
A simple analysis of the "phosphocreatine shuttle". Am J Physiol (1984) 2.31
Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation (1994) 2.21
The structure of the rigor complex and its implications for the power stroke. Philos Trans R Soc Lond B Biol Sci (2004) 2.17
Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest (1996) 2.09
Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest (1993) 2.04
Myosin motors: missing structures and hidden springs. Curr Opin Struct Biol (2001) 1.98
Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest (1998) 1.94
Spare the rod, spoil the regulation: necessity for a myosin rod. Proc Natl Acad Sci U S A (1997) 1.94
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci (2000) 1.86
Myosin light chain phosphorylation affects the structure of rabbit skeletal muscle thick filaments. Biophys J (1996) 1.75
ADP inhibition of myosin V ATPase activity. Biophys J (2000) 1.75
Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand (1999) 1.72
Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A (1995) 1.70
Phosphorylation of myosin in permeabilized mammalian cardiac and skeletal muscle cells. Am J Physiol (1986) 1.66
The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci U S A (1987) 1.64
Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A (1993) 1.62
Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation (2000) 1.58
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet (2002) 1.56
Independent assembly of 1.6 microns long bipolar MHC filaments and I-Z-I bodies. Cell Struct Funct (1997) 1.51
Measurements on permeabilized skeletal muscle fibers during continuous activation. Am J Physiol (1987) 1.49
Extracellular matrix elasticity directs stem cell differentiation. J Musculoskelet Neuronal Interact (2007) 1.47
Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol (1998) 1.47
Quantitative electrophoretic analysis of myosin heavy chains in single muscle fibers. J Appl Physiol (1985) (2001) 1.45
Actin and light chain isoform dependence of myosin V kinetics. Biochemistry (2000) 1.45
In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther (1996) 1.45
R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil (2000) 1.44
Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol (2000) 1.44
Adaptations in myosin heavy chain expression and contractile function in dystrophic mouse diaphragm. Am J Physiol (1993) 1.43
31P NMR spectroscopy, chemical analysis, and free Mg2+ of rabbit bladder and uterine smooth muscle. J Biol Chem (1986) 1.43
The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil (1997) 1.40
Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 1.35
Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation (1995) 1.34
The stretch-activation response may be critical to the proper functioning of the mammalian heart. Proc Natl Acad Sci U S A (1999) 1.31
Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation (1992) 1.29
Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther (2001) 1.28
Site-directed mutation of the trigger calcium-binding sites in cardiac troponin C. J Biol Chem (1989) 1.24
Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A (1999) 1.23
Two conserved lysines at the 50/20-kDa junction of myosin are necessary for triggering actin activation. J Biol Chem (2000) 1.21
Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther (2008) 1.18
Kinetic and spectroscopic evidence for three actomyosin:ADP states in smooth muscle. J Biol Chem (2000) 1.18
Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). J Med Genet (2004) 1.16
Velocity of shortening and myosin isozymes in two types of rabbit fast-twitch muscle fibers. Am J Physiol (1986) 1.15
Structural and functional responses of mammalian thick filaments to alterations in myosin regulatory light chains. J Struct Biol (1998) 1.12
Reliability of the evoked response in determining the paced ventricular rate and performance of the QT or rate responsive (TX) pacemaker. Pacing Clin Electrophysiol (1985) 1.09
Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation (2001) 1.09
Initiation and maturation of I-Z-I bodies in the growth tips of transfected myotubes. J Cell Sci (1999) 1.08
Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation (1991) 1.06
Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol (1990) 1.05
Thymosin-beta(4) changes the conformation and dynamics of actin monomers. Biophys J (2000) 1.05
Myosin phosphorylation in permeabilized rabbit psoas fibers. Am J Physiol (1985) 1.05
Muscle cell peeling from micropatterned collagen: direct probing of focal and molecular properties of matrix adhesion. J Cell Sci (1999) 1.04
Changes in interfilament spacing mimic the effects of myosin regulatory light chain phosphorylation in rabbit psoas fibers. J Struct Biol (1998) 1.02
A new moderately repetitive DNA sequence family of novel organization. Nucleic Acids Res (1987) 1.02
Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther (2000) 1.01
Myosin phosphorylation in smooth and skeletal muscles: regulation and function. Prog Clin Biol Res (1990) 1.01
Noninvasive measurement of gene expression in skeletal muscle. Proc Natl Acad Sci U S A (2000) 1.01
Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 0.97
Changes in fiber composition of soleus muscle during rat hindlimb suspension. J Appl Physiol (1985) (1988) 0.97
Efficient transmural cardiac gene transfer by intrapericardial injection in neonatal mice. J Mol Cell Cardiol (1999) 0.96
The ADP release step of the smooth muscle cross-bridge cycle is not directly associated with force generation. Biophys J (1999) 0.95
Myosin regulatory light chain phosphorylation and the production of functionally significant changes in myosin head arrangement on striated muscle thick filaments. Biophys J (1995) 0.94
Mutation of the high affinity calcium binding sites in cardiac troponin C. J Biol Chem (1992) 0.94
Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. Am J Cardiol (1994) 0.93
The possible relation between late pregnancy hypertension and 5-hydroxytryptamine levels in maternal blood. Br J Obstet Gynaecol (1979) 0.92
The light chain-binding domain of the smooth muscle myosin heavy chain is not the only determinant of regulation. J Biol Chem (1998) 0.91
Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunction. Circulation (1998) 0.91
Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol (2001) 0.91
Atrial synchronized ventricular pacing: contribution of the chronotropic response to improved exercise performance. Pacing Clin Electrophysiol (1983) 0.90
Function of the N-terminal calcium-binding sites in cardiac/slow troponin C assessed in fast skeletal muscle fibers. J Biol Chem (1991) 0.89
A gradient of myosin regulatory light-chain phosphorylation across the ventricular wall supports cardiac torsion. Cold Spring Harb Symp Quant Biol (2002) 0.88
Dispensability of the actin-binding site and spectrin repeats for targeting sarcomeric alpha-actinin into maturing Z bands in vivo: implications for in vitro binding studies. Dev Biol (1998) 0.88
Ventricular septal defect after myocardial infarction: assessment by cross sectional echocardiography with pulsed wave Doppler scanning. Br Heart J (1987) 0.88
Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice. J Appl Physiol (1985) (2010) 0.87
Comparison of resting hemodynamic indices and exercise performance during atrial synchronized and asynchronous ventricular pacing. Pacing Clin Electrophysiol (1983) 0.86
Influence of electrical stimulation on a fast-twitch muscle in aging rats. J Appl Physiol (1985) (1991) 0.86
Structural and kinetic studies of phosphorylation-dependent regulation in smooth muscle myosin. J Biol Chem (1998) 0.86